Research Analysts Set Expectations for CSTL Q1 Earnings

Castle Biosciences, Inc. (NASDAQ:CSTL) – Analysts at Leerink Partnrs issued their Q1 2026 EPS estimates for shares of Castle Biosciences in a research report issued to clients and investors on Friday, February 28th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings of ($0.57) per share for the quarter. The consensus estimate for Castle Biosciences’ current full-year earnings is $0.44 per share. Leerink Partnrs also issued estimates for Castle Biosciences’ Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.36) EPS and FY2027 earnings at ($1.32) EPS.

Other research analysts also recently issued research reports about the stock. Robert W. Baird upped their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Stephens reaffirmed an “overweight” rating and set a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Lake Street Capital upped their price objective on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. KeyCorp upped their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Scotiabank upped their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 6th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $40.00.

Castle Biosciences Trading Up 4.5 %

Shares of CSTL stock opened at $22.23 on Monday. The firm has a 50-day moving average price of $27.00 and a 200 day moving average price of $29.11. Castle Biosciences has a twelve month low of $16.97 and a twelve month high of $35.84. The company has a market capitalization of $622.60 million, a price-to-earnings ratio of 111.16 and a beta of 0.91. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02.

Insider Transactions at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,972 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $31.35, for a total value of $61,822.20. Following the completion of the transaction, the insider now owns 85,748 shares in the company, valued at $2,688,199.80. This represents a 2.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,771 shares of company stock worth $886,112. 7.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Covestor Ltd purchased a new position in Castle Biosciences in the 4th quarter worth approximately $25,000. R Squared Ltd purchased a new position in shares of Castle Biosciences during the 4th quarter valued at approximately $42,000. Quest Partners LLC boosted its stake in shares of Castle Biosciences by 54.4% during the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after buying an additional 1,522 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Castle Biosciences during the 4th quarter valued at approximately $128,000. Finally, US Bancorp DE boosted its stake in shares of Castle Biosciences by 1,889.2% during the 3rd quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after buying an additional 4,383 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.